Literature DB >> 14584930

Nitroaryl phosphoramides as novel prodrugs for E. coli nitroreductase activation in enzyme prodrug therapy.

Longqin Hu1, Chengzhi Yu, Yongying Jiang, Jiye Han, Zhuorong Li, Patrick Browne, Paul R Race, Richard J Knox, Peter F Searle, Eva I Hyde.   

Abstract

Cyclic and acyclic nitroaryl phosphoramide mustard analogues were activated by E. coli nitroreductase, an enzyme explored in GDEPT. The more active acyclic 4-nitrobenzyl phosphoramide mustard (7) showed 167 500x selective cytotoxicity toward nitroreductase-expressing V79 cells with an IC(50) as low as 0.4 nM. This is about 100x more active and 27x more selective than CB1954 (1). The superior activity was attributed to its better substrate activity (k(cat)/K(m) 19x better than 1) and/or excellent cytotoxicity of phosphoramide mustard released.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14584930     DOI: 10.1021/jm034133h

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  5 in total

1.  Exploiting the drug-activating properties of a novel trypanosomal nitroreductase.

Authors:  Belinda S Hall; Xinghua Wu; Longqin Hu; Shane R Wilkinson
Journal:  Antimicrob Agents Chemother       Date:  2009-12-22       Impact factor: 5.191

2.  A phase I/II clinical trial in localized prostate cancer of an adenovirus expressing nitroreductase with CB1954 [correction of CB1984].

Authors:  Prashant Patel; J Graham Young; Vivien Mautner; Daniel Ashdown; Sarah Bonney; Robert G Pineda; Stuart I Collins; Peter F Searle; Diana Hull; Elizabeth Peers; John Chester; D Michael Wallace; Alan Doherty; Hing Leung; Lawrence S Young; Nicholas D James
Journal:  Mol Ther       Date:  2009-04-14       Impact factor: 11.454

3.  An essential type I nitroreductase from Leishmania major can be used to activate leishmanicidal prodrugs.

Authors:  Andrew A Voak; Vithurshaa Gobalakrishnapillai; Karin Seifert; Edina Balczo; Longqin Hu; Belinda S Hall; Shane R Wilkinson
Journal:  J Biol Chem       Date:  2013-08-14       Impact factor: 5.157

Review 4.  Prodrugs and prodrug-activated systems in gene therapy.

Authors:  Semira Sheikh; Daniel Ernst; Armand Keating
Journal:  Mol Ther       Date:  2021-04-06       Impact factor: 11.454

Review 5.  Bystander or no bystander for gene directed enzyme prodrug therapy.

Authors:  Gabi U Dachs; Michelle A Hunt; Sophie Syddall; Dean C Singleton; Adam V Patterson
Journal:  Molecules       Date:  2009-11-10       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.